Pharmaceutical firm Cytogen has regained the rights to ex vivo prostate cancer immunotherapy using prostate-specific membrane antigen (PSMA) following the expiration of its agreement with Northwest Biotherapeutics of Bothell, WA. The agreement, which ends January 17, 2003, gave Northwest a license to develop and commercialize ex vivo immunotherapy products for prostate cancer that are produced by pulsing isolated populations of a patient’s antigen-presenting cells.
Northwest Biotherapeutics, which terminated the program for funding purposes in November 2002, advanced to the initiation of phase III clinical trials, according to Princeton, NJ-based Cytogen. Cytogen will be seeking other corporate collaborations or partnerships to help it realize the clinical and commercial potential of the immunotherapy, said the company’s president and CEO Michael Becker.
By AuntMinnie.com staff writers
January 3, 2003
Related Reading
Cytogen gets new CEO, December 19, 2002
MRI agent detects lymph node disease in prostate and renal cancers, December 4, 2002
Cytogen returns to Nasdaq compliance, November 12, 2002
Cytogen revenue up in third quarter, November 6, 2002
Cytogen implements reverse stock split, October 28, 2002
Copyright © 2003 AuntMinnie.com
